First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

Frontiers in Oncology
Ajaz Bulbul, Hatim Husain

Abstract

First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line management of non-small cell lung cancer (NSCLC) patients with activating mutations within the kinase domain of the epidermal growth factor receptor gene (1, 2). Resistance to targeted therapy can develop after 9-11 months (3-8). Third generation inhibitors were developed to target the EGFR T790M clone, which is the most common dominant second site resistance mutation after first or second generation inhibitors. Osimertinib received full FDA approval for the second-line treatment of advanced NSCLC based on a phase III study comparing the compound to chemotherapy. Recent data demonstrates an important impact for osimertinib in the front-line space based on results comparing the compound to first-generation erlotinib or gefitinib therapy.

References

Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardVincent A Miller
Jan 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rafael RosellMiquel Taron
May 3, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ross A SooRichie Soong
Aug 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardVincent A Miller
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jul 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suresh S RamalingamMichael Boyer
Aug 14, 2012·The Journal of Pharmacology and Experimental Therapeutics·Flavio SolcaGuenther R Adolf
Jan 15, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·S PopatM O'Brien
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jan 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardPasi A Jänne
Apr 17, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sung Hee LimMyung-Ju Ahn
Apr 30, 2015·The New England Journal of Medicine·Pasi A JänneMalcolm Ranson
May 6, 2015·Nature Reviews. Clinical Oncology·David Killock
May 13, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew J NiederstJeffrey A Engelman
Jun 25, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christina S BaikLaura Q Chow
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter BallardDarren Cross
Aug 20, 2016·JAMA Oncology·Geoffrey R OxnardLynette M Sholl
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloUNKNOWN ESMO Guidelines Committee
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangPasi A Jänne
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L Paz-AresK Park
Jul 1, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Zhen WangYi-Long Wu
Aug 15, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaGregory Masters
Aug 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suresh S RamalingamPasi A Jänne
Aug 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Surein ArulanandaThomas John
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators

❮ Previous
Next ❯

Citations

Nov 6, 2018·Journal of Cellular Physiology·Saeed SamarghandianTahereh Farkhondeh
Nov 12, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Vignesh KumarRaghuraman Kannan
Sep 9, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dan YanDouglas K Graham
Dec 5, 2019·Journal of Chemical Information and Modeling·Luca Pinzi, Giulio Rastelli

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02296125
NCT01802632
NCT02228369
NCT03122717

Software Mentioned

FLAURA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.